Artykuły w Czytelni Medycznej o SARS-CoV-2/Covid-19

Chcesz wydać pracę doktorską, habilitacyjną czy monografię? Zrób to w Wydawnictwie Borgis – jednym z najbardziej uznanych w Polsce wydawców książek i czasopism medycznych. W ramach współpracy otrzymasz pełne wsparcie w przygotowaniu książki – przede wszystkim korektę, skład, projekt graficzny okładki oraz profesjonalny druk. Wydawnictwo zapewnia szybkie terminy publikacji oraz doskonałą atmosferę współpracy z wysoko wykwalifikowanymi redaktorami, korektorami i specjalistami od składu. Oferuje także tłumaczenia artykułów naukowych, skanowanie materiałów potrzebnych do wydania książki oraz kompletowanie dorobku naukowego.

Poniżej zamieściliśmy fragment artykułu. Informacja nt. dostępu do pełnej treści artykułu tutaj
© Borgis - Nowa Medycyna 6/2002
Tadeusz Pieńkowski
Postępy w chemicznym leczeniu chorych na raka piersi
Advances in chemotherapy of breast cancer
z Kliniki Nowotworów Piersi i Chirurgii Rekonstrukcyjnej Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie w Warszawie
Kierownik Kliniki: dr hab. med. Tadeusz Pieńkowski
Streszczenie
In the most cases invasive breast cancer is systemic disease. Progress in the treatment of this cancer has been achieved. From the middle 70-ies several big randomized trials have been performed. Results of these trials cleary demonstrates that adjuvant systemic treatment can prolong overall survival and indicatins to the adjuvant has been establised. Systemic adjuvant treatment has been established as part of the radical treatment in patients in I, II and III stage. In the treatment of advenced breast cancer some new cytostatics and hormonal drugs have been introduced to the clinical practice. Drugs which are active in disseminated disease will be investigated in adjuvant treatment.

Powyżej zamieściliśmy fragment artykułu, do którego możesz uzyskać pełny dostęp.

Płatny dostęp do wszystkich zasobów Czytelni Medycznej

Aby uzyskać płatny dostęp do pełnej treści powyższego artykułu oraz WSZYSTKICH około 7000 artykułów Czytelni, należy wprowadzić kod:

Kod (cena 30 zł za 30 dni dostępu) mogą Państwo uzyskać, przechodząc na tę stronę.
Wprowadzając kod, akceptują Państwo treść Regulaminu oraz potwierdzają zapoznanie się z nim.

Piśmiennictwo
1. Pisani P. et al.: Estimates of the world-wide mortality from eighteen major cancers in 1985. Implications from prevention and projections of future burden. Int J. Cancer, 1993, 55:891-903. 2. Early Breast Cancer Trialialist´s Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet, 1998, 352:930-942. 3.Early Breast Cancer Trialialist´s Colloborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet, 1998, 351:1451-1467. 4. Hortobagyi G.N., Piccart M.J.: Current management of advanced breast cancer. Semin. Oncol. 23 (supp.11), 1996, 1-5. 5.Goldhirsch A. et al.: Meeting higlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J. Natl. Cancer. Inst., 1998, 90:1601-1608. 6. Early Breast Cancer Triaialit´s Collaborative Group. Ovarian ablation in early breast cancer: an overview of the randomized trials. Lancet, 1996, 348:1189-96. 7. Bonadonna G. et al.: Adjuvant cyclophophamide, methotrexate and fluorouracil in node positive breast cancer: the results of 20 years of follow-up. N. Eng. J. Med., 1995, 332:901-906. 8. Misset J.L. et al.: Adjuvant treatment of node positive breast cancer with cyclophpsphamide, doxorubicin fluorouracil and vincristine versus cyclophpsphamide, methotrexate, and fluorouracil: final report after a 16 year median follow-up duration. J. Clin. Oncol., 1996, 14:1136-1145. 9. Levine M.N. et al.: Randomised trial of intensive cyclophpsphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node positive breast cancer. National Cancer Institute of Canada Clinical Trialist Group. J. Clin. Oncol., 1998, 16:2651-2658. 10. Fisher B. et al.: Two month of doxorubicin-cyclophamiphamide with and without interval reinduction therapy compared with 6 month of cyclophosphamide, metotrexate, and fluorouracil in possitive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Breast and Bowel Project B-15. J. Clin. Oncol.,1990, 8:1483-1496. 11. Wood W.C. et al.: Dose and dose intensity of adjuvant chemotherapy for stage II node positive, breast carcinoma. N. Eng. J. Med., 1994, 330:1253-1259. 12. Bonadonna G. et al.: Sequetial or alternating doxorubicin and CMF in breast cancer with more than three positive nodes: Ten-year results JAMA, 1995, 273:542-547. 13. Henderson I.C. et al.: Improved disease-free survival (DFS) and overall survival (OS) from addition of sequetial paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc. Am. Soc. Clin. Oncol., 1998, 17:101. 14. Ueno N.T. et al.: Combined-modality treatment of inflamatory breast carcinoma: twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemotherapy and Pharmacology, 1994, 40 (4):321-329. 15. Bonadonna G., Valagussa P.: Primary chemotherapy in operable breast cancer. Semin. Oncol., 1996, 23:464-474. 16. Fisher B. et al.: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer. Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J. Clin. Oncol., 1997, 15:2483-93. 17. Pieńkowski T.: Czynniki predykcyjne u chorych na raka sutka. Nowotwory, 2000, 50:165-170. 18. Honing S.F.: Hormonal therapy and chemotherapy, str. 669-734. In: Disease of the Breast pod redakcją Harris J.R., Morrow M., Lippan M.E. Wyd.: Lippincott-Raven Publishers Filadelfia, 1996. 19. Ranson M.R. et al.: Treatment of advanced breast cancer with sterically stabized liposomal doxorubicin: Results of a multicenter phase II trial. J. Clin. Oncol., 1997, 15:3185-3191. 20. Trudeau M.E.: Phase I-II studies of docetaxel as single agent in the treatment of metastatic breast cancer. Semin. Oncol., 1999, 26:21-26. 21. Ravdin P.M.: The international experience with docetaxel in the treatment of breast cancer. Oncology, 1997, 11:38-42. 22. Burstein H.J. et al.: Weekly docetaxel (Taxotere) for metastacic breast cancer: A phase II trial. Proc. Am. Soc. Clin. Oncol., 1999, 18:127a. 23. Nabcholtz J.M. et al.: Prospective randomized trial of docetaxel vs mitomycin C plus vinblastin in patients with metastatic breast cancer progressing despite previous anthracyclin-containig chemotherapy. J. Clin. Oncol., 1999, 17:1413-1424. 24. Chan S. et al.: Prospective randomised trial of docetaxel vs doxorubicin in patients with metastacic bresat cancer. J. Clin. Oncol., 1999, 17:2341-2354. 25. Nabcholtz J.M. et al.: Docetaxel and antracycline polychemotherapy in the treatment of advanced breast cancer. Semin. Oncol., 1999, 26:47-52. 26. Nabcholtz J.M. et al.: A phase III trial compoaring, doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cycliphasphamide (AC) as first line chemotherapy for MBC. Proc. Am. Soc. Clin. Oncol., 1999, 18:485. 27. Holmes F.A. et al.: Phase II trial of Taxol an active drug in the treastment of metastatic breast cancer. J. Natl. Cancer Inst., 1991, 83:1797-1805. 28. Abrams J.S. et al.: Paclitaxel activity in heavily pretreated breast cancer a National Cancer Institute treatment referal center trial. J. Clin. Oncol., 1995, 13:2056-2065. 29. Miller K.D. et al.: Taxanes in the treatment of breast cancer. A prodigy comes of age. Cancer Ivevest, 1998, 17:121-136. 30. Seidman A.D. et al.: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J. Clin. Oncol., 1998, 16:3353-3361. 31. Płużańska A. et al.: Phase III multicenter trial comparing Taxol/doxorubicin (AT) vs 5-fluorouracil/doxorubicin and cyclophosphamide (FAC) as first line treatment for patients with metastatic breast cancer Brest cancer reseach and treatment 57, 21, 1999. 32. Livingston R.B. et al.: Dose-intensive vinorelbine with concurent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol., 1997, 15:1395-1400. 33. Spielman M. et al.: Phase II trial of vinorelbin/doxorubicin as first line therapy of advanced breast cancer. J. Clin. Oncol., 1994, 12:1764-1770. 34. Pieńkowski T. et al.: Vinorelbine and five-days continous infusion of 5-fluorouracil in preatreated breast cancer patients breast cancer research and treatment. 1999, 57:338. 35. Blum J.L. et al.: Multicer phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol., 1999, 17:485-493. 36. O´Shaughnessy J. et al.: A randomized phase II study of Xeloda (capecytabine) vs CMF as first line chemotherapy of breast cancer in women aged >= 55 years. Proc. Am. Soc. Clin. Oncol., 1998, 17:398. 37. Osborne C.K.: Tamoxifen in the treatment of breast cancer. N. Eng. J. Med., 1998, 339:1609-1618. 38.Hayes D.F. et al.: Randomized comparison of tamoxifen and two separate doses of toremifen in postmenopausal patients with metastatic breast cancer. J. Clin. Oncol., 1995, 13:2556-2566. 39. Cummings S.R. et al.: The effects of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomised trial: Multiple outcomes of raloxifen evaluation. JAMA, 1999, 281:2189-2197. 40. Howell A. et al.: Response to a specific antiestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet, 1995, 345:29-30. 41. Jonat W. et al.: A randomized study to compare the effect of the luteizing hormone-relaleasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre and perimenopausal patients with advanced breast cancer. Eur. J. Cancer, 1995, 31A:137-142. 42. Buzdar A.U. et al.: Aromatase inhibitors in metastatic breast cancer. Semin. Oncol., 1996, 23:28-32. 43. Buzdar A.U. et al.: Anastrosole vs megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trial: Arimidex Study Group. Cancer, 1998, 83:1142-1152. 44. Dombernowsky P. et al.: Letrosole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol., 1998, 16:453-461. 45. Kaufman M. et al.: Survival advantage of examestan (Aromasin) over megestrol acetate in postmenopausal women with advanced breast cancer refractory to tamoxifen: Results of a phase II randomized double blind study. Proc. Am. Soc. Clin. Oncol., 1999, 18:109. 46. Mouridsen H. et al.: Letrozole (Femara) versus tamoxifen: Preliminary data of a first-line clinical trial in postmenopausal women with locally advanced or metastatic breast cancer. Eur. J. Cancer, 2000, 36 (5) 220:11-12. 47. Robertson J. et al.: Anastrozole (Arimidex) versust amoxifen as first-line therapy for advanced breast cancer (ABC) in post menopausal (PM) women – prospective combined analysis from two international trial. Eur. J. Cancer, 2000, 36 (5):219. 48. Paridaens R. et al.: Examestane (Aromasin) is active and well tolerated as first-line hormanal therapy of metastatic breast cancer patients: Results of a randomized phase II trial. Proc. Am. Soc. Clin. Oncol., 2000, 19:316. 49. Pegram M.D. et al.: HER-2/neu as a predictive marker of response to breast therapy. Breast cancer research and treatment. 1998, 52:65-77. 50. Cobleigh M.A. et al.: Efficacy and safety of Herceptin (humanized anti HER2 antibody) as single agent in 222 women with HER2 overexpression who relapsed followig chemotherapy for metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., 1998, 17:337. 51. Norton L. et al.: Overvall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2– overexpression (HER2+) metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol., 1999, 18:483.
Nowa Medycyna 6/2002
Strona internetowa czasopisma Nowa Medycyna